Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
종목 코드 RGNT
회사 이름Regentis Biomaterials Ltd
상장일Dec 04, 2025
CEOHazum (Eli)
직원 수- -
유형Ordinary Share
회계 연도 종료- -
주소60, Medinat Hyahudim
도시HERZLIYA
증권 거래소NASDAQ OMX – NASDAQ Basic Amex
국가Israel
우편 번호4676652
전화97246265502
웹사이트https://www.regentis.co.il/
종목 코드 RGNT
상장일Dec 04, 2025
CEOHazum (Eli)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음